ReviewYonsei medical journal2013
Outcome predictors for intestinal Behçet's disease.
Review in Yonsei medical journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).Gut and liver · 2023Trial
- Management of Severe Behçet's Disease.Current rheumatology reports · 2026Review
- Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan.Journal of gastroenterology · 2025Observational
- Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.Yonsei medical journal · 2023Article
- The treatment principles and targets for intestinal Behcet's disease.Therapeutic advances in gastroenterology · 2023Review
- Clinical Course of Patients with Intestinal Behçet's Disease According to Consensus-Based Diagnostic Categories.Gut and liver · 2022Article
- Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.Therapeutic advances in gastroenterology · 2022Article
- Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational studyIntestinal research · 2021Article
- Advances in Management of Intestinal Behçet's Disease: A Perspective From Gastroenterologists.Journal of rheumatic diseases · 2021Review
- Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.Current gastroenterology reports · 2020Review
- The outcomes and risk factors of early readmission in patients with intestinal Behçet's disease.Clinical rheumatology · 2018Article
- Updated treatment strategies for intestinal Behçet's disease.The Korean journal of internal medicine · 2018Review
- Incidence and clinical outcomes of intestinal Behçet's disease in Korea, 2011-2014: a nationwide population-based study.Journal of gastroenterology · 2017Article
- Intestinal Behçet and Crohn's disease: two sides of the same coin.Pediatric rheumatology online journal · 2017Review
- Update on the Medical Management of Gastrointestinal Behçet's Disease.Mediators of inflammation · 2017Review
- Usefulness of Measuring Serum Procalcitonin Levels in Patients with Inflammatory Bowel Disease.Gut and liver · 2016Article
- Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?Yonsei medical journal · 2016Review
- Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease.Digestive diseases and sciences · 2015Article
- Clinical Characteristics and Treatment Outcomes of Cryptogenic Multifocal Ulcerous Stenosing Enteritis in Korea.Digestive diseases and sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a multisystem inflammatory disorder that presents as recurrent oral and genital ulcers in conjunction with other dermatological and ocular manifestations. The prevalence of BD is higher in Middle and East Asia than in Western countries. Intestinal BD is a specific subtype of BD, characterized by intestinal ulcers and associated gastrointestinal symptoms. Similar to inflammatory bowel disease, intestinal BD exhibits a fluctuating disease course with repeated episodes of relapse and remission that necessitate adequate maintenance therapy after achievement of clinical remission. Medical treatment of intestinal BD is largely empirical since well-controlled studies have been difficult to perform due to the heterogeneity and rarity of the disease. To date, 5-aminosalicylic acid, systemic corticosteroids, and immunosuppressants have been used anecdotally to treat intestinal BD. The clinical course of intestinal BD shows considerable variability, and the exact point at which more potent agents such as immunosuppressants should be used has not yet been elucidated. Given the difficulty in predicting which patients will experience complicated disease courses and the fact that these drugs are related with certain risk resulting from immunosuppression, proper identification of prognostic factors in intestinal BD may allow physicians to implement tailored medical therapy and individualized patient monitoring based on risk stratification. In this review, the impact of baseline characteristics on the long-term course of intestinal BD, prognostic factors during various medical therapies, and outcome predictors related to surgery will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.